ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study
Open Access
- 21 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 145 (3), 765-774
- https://doi.org/10.1007/s00432-018-02835-6
Abstract
Purpose Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival of cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which is designed for follow-up of cancer patients receiving immune checkpoint inhibitors (ICI). Purpose of the current study is to investigate whether symptoms collected by Kaiku Health ePRO tool on cancer patients receiving immune checkpoint inhibitors (ICI) follows to symptoms reported in clinical trials and whether coupling of specific symptoms does occur. Methods We retrospectively collected data on symptom timing and severity, and QoL of patients followed with Kaiku Health IO module in two Finnish cancer centers between 2017 and 2018. Kaiku Health IO module consists of 18 adaptive questions, which assess the presence and severity of symptoms. Patients were requested (via e-mail) to fill online symptom questionnaires with 3–7 day interval and QoL questionnaires (QLQ-C30) with 1–2 month interval. Results The IO module was used to follow 37 patients who had filled in total 559 symptom questionnaires. There was good adherence to ePRO follow-up with a median of 11 questionnaires filled per patient. The reported symptoms and their severity follow closely what has been seen in clinical trials investigating ICIs. Correlation analysis of the symptoms showed the strongest positive correlations between itching and rash; nausea and vomiting, decreased appetite, or stomach pain; cough and shortness of breath. Conclusions The results of the current study suggest that real-world symptom data collected through the ePRO application on cancer patients receiving ICI therapy aligns with the data from clinical trials. Correlations between different symptoms occur, which might reflect therapeutic efficiency, side effects, or tumor progression. These correlations should be further investigated with data coupled to clinical outcomes.Keywords
This publication has 46 references indexed in Scilit:
- Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patientsCritical Reviews in Oncology/Hematology, 2012
- Quality Improvement in Cancer Symptom Assessment and Control: The Provincial Palliative Care Integration Project (PPCIP)Journal of Pain and Symptom Management, 2012
- Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical TrialJournal of Clinical Oncology, 2011
- Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: Secondary outcomes of a randomised controlled trialEuropean Journal of Cancer, 2010
- Health care providers underestimate symptom intensities of cancer patients: A multicenter European studyHealth and Quality of Life Outcomes, 2010
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical OutcomesJNCI Journal of the National Cancer Institute, 2009
- Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.Supportive Care in Cancer, 2008
- The clinical value of quality of life assessment in oncology practice—a qualitative study of patient and physician viewsPsycho‐Oncology, 2007
- Computerized Symptom and Quality-of-Life Assessment for Patients With Cancer Part II: Acceptability and UsabilityOncology Nursing Forum, 2004
- Measuring Quality of Life in Routine Oncology Practice Improves Communication and Patient Well-Being: A Randomized Controlled TrialJournal of Clinical Oncology, 2004